BioCentury
ARTICLE | Company News

Emergent BioSolutions cancer, hematology news

September 14, 2015 7:00 AM UTC

Emergent will spin out its biosciences business into a stand-alone, publicly traded company. The spinout will focus on oncology and hematology therapeutics and will receive $50-$70 million in cash fro...